American Society of Hematology

ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)

Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle Sickle Cell Disease…